☆ 4.7 Review

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning

Chung Shing Rex Ha et al.

PLoS One (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation

Fabienne Mueller et al.

Summary: KRAS-mutant cells escape ferroptosis by upregulating FSP1 expression, leading to resistance to ferroptosis and promoting tumor formation and progression. Overexpression of FSP1 is sufficient to promote KRAS WT cell transformation, but inhibition of FSP1 can effectively induce ferroptosis only in the absence of ferroptosis resistance mutations. Therefore, ferroptosis-inducing therapy should be combined with FSP1 inhibitors for efficient therapy of KRAS-mutant cancers.

CELL DEATH AND DIFFERENTIATION (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting glutamine metabolism as a therapeutic strategy for cancer

Jonghwa Jin et al.

Summary: This review summarizes the mechanisms involved in glutamine metabolism and discusses strategies for targeting glutamine metabolism for cancer treatment. It also explores the mechanisms underlying cancer cell resistance to agents that target glutamine metabolism and strategies for overcoming resistance. Furthermore, it discusses the effects of glutamine blockade on the tumor microenvironment and explores strategies to maximize the utility of glutamine blockers as a cancer treatment.

EXPERIMENTAL AND MOLECULAR MEDICINE (2023)

Add to Collection

Article Cell Biology

A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers

Rongjie Cheng et al.

Summary: This study identifies RASON as a positive regulator of oncogenic RAS signaling and reveals its aberrant overexpression in pancreatic ductal adenocarcinoma. RASON promotes tumor cell proliferation and tumor growth by sustaining the hyperactive state of KRAS through inhibiting GTP hydrolysis. Deprivation of RASON sensitizes KRAS mutant pancreatic cancer cells to EGFR inhibitors.

CELL RESEARCH (2023)

Add to Collection

Article Gastroenterology & Hepatology

Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis

Andrea Costamagna et al.

Summary: High expression of p130Cas is associated with higher histologic grade and poor prognosis in PDAC. Deletion of p130Cas inhibits acinar-derived tumorigenesis and progression by suppressing PI3K-AKT signaling. Targeting the PI3K pathway may be a rational therapeutic strategy for tumors with high expression of p130Cas.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis

Wenjie Ge et al.

Summary: miR-802 is a highly abundant and acinar-enriched pancreatic miRNA that is silenced during early stages of injury or oncogenic Kras(G12D)-induced transformation. Genetic ablation of mir-802 cooperates with Kras(G12D) by promoting ADM formation. miR-802 deficiency results in de-repression of the miR-802 targets Arhgef12, RhoA, and Sdc4, activation of RhoA, and induction of the downstream RhoA effectors ROCK1, LIMK1, COFILIN1, and EZRIN, thereby increasing F-actin rearrangement.

GASTROENTEROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ

Yi Liu et al.

Summary: PPARδ signaling pathway plays a key role in the progression of pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC), inducing an immunosuppressive microenvironment through the upregulation of CCL2, driving the disease progression.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Sahar F. Bannoura et al.

Summary: KRAS mutations are common in cancer, and recent advancements have shown that small molecule inhibitors can be developed against KRAS G12C, although there is still no agent to target KRAS G12D. However, significant progress has been made in developing compounds that can bind to and inhibit KRAS G12D, including MRTX1133. Additionally, an immunotherapeutic approach using adoptive T-cell transfer has shown promise in targeting G12D in pancreatic cancer.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Targeting KRAS in PDAC: A New Way to Cure It?

Qianyu He et al.

Summary: Pancreatic cancer is a highly challenging malignant tumor with poor prognosis. Pancreatic ductal adenocarcinoma (PDAC) is the most common type, with KRAS being the most predominant mutated gene. KRAS has been considered undruggable for decades, but the advent of KRAS(G12C) inhibitors has provided hope. While G12C inhibitors show efficacy against non-small-cell lung cancer (NSCLC), their effectiveness in PDAC, where G12C mutation is rare, is limited. Hence, targeting KRAS G12D/V, which forms the majority of KRAS mutations in PDAC, is gaining attention as a potential therapy.

CANCERS (2022)

Add to Collection

Article Oncology

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers

Husain Yar Khan et al.

Summary: The XPO1 inhibitor can enhance the anticancer activity of KRAS G12C inhibitors in preclinical cancer models. The combination treatment synergistically inhibits the proliferation of KRAS G12C mutant cancer cells and reduces tumor burden, leading to improved survival in vivo.

CANCER RESEARCH COMMUNICATIONS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation

Xian Zhou et al.

Summary: The study found that Rnf43 is a tumor suppressor in the prevention of pancreatic malignant transformation. Using a genetically reconstituted mouse model and treatment with Wnt/beta-catenin signaling inhibitors, the pathological process from pancreatic cyst to cancer can be recapitulated.

ANIMAL MODELS AND EXPERIMENTAL MEDICINE (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Post-translational modification of KRAS: potential targets for cancer therapy

Wei-hua Wang et al.

Summary: This review discusses the regulatory mode of post-translational modifications on KRAS, including prenylation, phosphorylation, and more, while highlighting recent studies targeting these modifications that have shown potent anti-tumor activities.

ACTA PHARMACOLOGICA SINICA (2021)

Add to Collection

Article Oncology

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Chen Liu et al.

Summary: The study evaluated the efficacy and synergistic mechanisms of a novel SHP2 inhibitor, TNO155, in combination with various drugs in different cancer models. Results demonstrated that TNO155 effectively blocks tumor-promoting and immune-suppressive RTK signaling, providing a rationale for clinical evaluation of these combinations.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Immunology

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Carmine Fedele et al.

Summary: The combination of SHP2 inhibitor and KRAS (G12C) inhibitor shows significant survival benefits in PDAC and NSCLC, inducing favorable changes in the tumor microenvironment by reducing myeloid suppressor cells, increasing CD8(+) T cells, and enhancing sensitivity to PD-1 blockade.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis

Hong Hua Yan et al.

Summary: The study revealed that ANGPTL4 plays a critical role in KRAS(G12D)-induced ADM, promoting its progression and influencing PDAC development by regulating periostin. The ANGPTL4/periostin axis is considered a potential therapeutic target for ADM-derived PDAC.

CANCER LETTERS (2021)

Add to Collection

Editorial Material Cell Biology

Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation

Howard C. Crawford

Summary: PDAC, one of the deadliest cancers, is characterized by oncogenic mutations in the KRAS gene. Targeting KRAS directly has been challenging, but recent success in certain mutants indicates a promising new era in therapy. Understanding resistance mechanisms to KRAS inhibitors is crucial for improving PDAC treatment outcomes.

GENES & DEVELOPMENT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1

Han Yan et al.

Summary: The restoration of wild-type KRAS expression in human PDAC cell lines significantly attenuates malignancy, positively regulating the HIPPO signaling pathway. In contrast, loss of wild-type KRAS leads to functional activation of YAP1 and enhanced tumor malignancy in PDAC cells, providing insights into therapeutic strategies targeting KRAS.

ONCOGENE (2021)

Add to Collection

Article Multidisciplinary Sciences

A gene-environment-induced epigenetic program initiates tumorigenesis

Direna Alonso-Curbelo et al.

Summary: The combination of Kras mutation and tissue damage leads to a unique chromatin state in pancreatic epithelium, distinguishing neoplastic transformation from normal regeneration and promoting malignant evolution. Within 48 hours of pancreatic injury, this cancer-associated epigenetic state involves a chromatin switch that contributes to dysregulation of genes defining human pancreatic cancer. The study demonstrates how gene-environment interactions rapidly produce gene-regulatory programs dictating early neoplastic commitment.

NATURE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas

Zonera Hassan et al.

Summary: The Nfkb2 gene is required for cancer initiation and progression in Kras(G12D)-driven models, mechanistically connected to proliferative pathways. However, Nfkb2 is dispensable in PDAC models relying on the simultaneous expression of the Kras oncogene and mutated p53 tumor suppressor.

PANCREATOLOGY (2021)

Add to Collection

Review Oncology

Targeting KRAS in pancreatic cancer: new drugs on the horizon

Sahar F. Bannoura et al.

Summary: KRAS is a commonly mutated oncogene in all cancers, with over 90% mutation rate in pancreatic ductal adenocarcinoma. Despite being considered undruggable for a long time, specific mutant KRAS inhibitors have been discovered recently.

CANCER AND METASTASIS REVIEWS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

D. Lucas Kerr et al.

Summary: SHP2, a nonreceptor protein tyrosine phosphatase, was considered 'undruggable' for decades, but has now become a potential target with the advent of allosteric inhibitors. These inhibitors show promise in preclinical cancer models and may also have immunomodulatory effects in certain tumor microenvironment cells. Clinical evaluation of the first generation of allosteric inhibitors will determine their safety, tolerability management, and antitumor efficacy for future applications.

CURRENT OPINION IN CHEMICAL BIOLOGY (2021)

Add to Collection

Article Cell Biology

USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer

Pingping Hou et al.

Summary: The study uncovers USP21 as a driver of KRAS*-independent PDAC growth by inducing macropinocytosis, which maintains intracellular amino acid levels. USP21 may play a role in affecting responsiveness to emergent anti-KRAS* therapy.

GENES & DEVELOPMENT (2021)

Add to Collection

Review Medicine, General & Internal

Pancreatic Cancer: A Review

Wungki Park et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer with increasing incidence each year, resulting in a high percentage of patients being diagnosed with advanced disease. Current cytotoxic therapies for PDAC are moderately effective, emphasizing the importance of multidisciplinary management, comprehensive germline testing, and integrated supportive care for all patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis

Edoardo Del Poggetto et al.

Summary: Inflammation plays a key role in promoting pancreatic ductal adenocarcinoma (PDAC), especially in the presence of KRAS mutations. Researchers have found that a transient inflammatory event can prime pancreatic epithelial cells for subsequent transformation by oncogenic KRAS, even long after the inflammation has resolved. This adaptation allows for the reactivation of acinar-to-ductal metaplasia (ADM) in response to recurring inflammatory events, potentially offering a protective mechanism against tissue damage.

SCIENCE (2021)

Add to Collection

Article Oncology

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer

Carmine Carbone et al.

Summary: Intratumoral injection of IMO-2125 triggers immune response against both local and distant tumors, showing potent antitumor activity in high immunogenic subtype of pancreatic cancer models. Moreover, the combination of intratumoral IMO-2125 with systemic anti-PD1 demonstrates strong antitumor effects even in pancreatic cancer models with low immunogenic potential. This study provides a rationale for translating this strategy into clinical practice.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

Louis Buscail et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Oncology

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment

Prasenjit Dey et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Carcinogenesis of Pancreatic Ductal Adenocarcinoma

Peter Storz et al.

GASTROENTEROLOGY (2020)

Add to Collection

Review Immunology

Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research

Zhidong Wang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo

Kotaro Sakamoto et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Cell Biology

USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation

Pingping Hou et al.

GENES & DEVELOPMENT (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Development of targeted protein degradation therapeutics

Philip P. Chamberlain et al.

NATURE CHEMICAL BIOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry

Hyuna Sung et al.

LANCET PUBLIC HEALTH (2019)

Add to Collection

Article Medicine, Research & Experimental

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Andrew M. Waters et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

Add to Collection

Article Oncology

Zeb1 in Stromal Myofibroblasts Promotes Kras-Driven Development of Pancreatic Cancer

Irene Sangrador et al.

CANCER RESEARCH (2018)

Add to Collection

Article Cell Biology

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers

Robert J. Nichols et al.

NATURE CELL BIOLOGY (2018)

Add to Collection

Article Oncology

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

Carmine Fedele et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Multidisciplinary Sciences

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

Giannicola Genovese et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer

Prasenjit Dey et al.

NATURE (2017)

Add to Collection

Article Gastroenterology & Hepatology

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis

Maria Teresa Salcedo Allende et al.

PANCREAS (2017)

Add to Collection

Article Oncology

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

Qiong J. Wang et al.

CANCER IMMUNOLOGY RESEARCH (2016)

Add to Collection

Article Medicine, General & Internal

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang-Gillam et al.

LANCET (2016)

Add to Collection

Article Multidisciplinary Sciences

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Ying-Nan P. Chen et al.

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey et al.

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Piro Lito et al.

SCIENCE (2016)

Add to Collection

Article Biology

Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism

Hongyun Zhao et al.

ELIFE (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Ras activation revisited: role of GEF and GAP systems

Anne Hennig et al.

BIOLOGICAL CHEMISTRY (2015)

Add to Collection

Article Oncology

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Piergiorgio Pettazzoni et al.

CANCER RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Andrea Viale et al.

NATURE (2014)

Add to Collection

Article Pharmacology & Pharmacy

Selective Induction of Apoptosis: Promising Therapy in Pancreatic Cancer

Zuojia Liu et al.

CURRENT PHARMACEUTICAL DESIGN (2013)

Add to Collection

Article Pharmacology & Pharmacy

Rational Drug Design: The Search for Ras Protein Hydrolysis Intermediate Conformation Inhibitors with Both Affinity and Specificity

Xiliang Zheng et al.

CURRENT PHARMACEUTICAL DESIGN (2013)

Add to Collection

Article Pharmacology & Pharmacy

A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells

Dan Li et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)

Add to Collection

Article Multidisciplinary Sciences

p53 status determines the role of autophagy in pancreatic tumour development

Mathias T. Rosenfeldt et al.

NATURE (2013)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia

G. Shi et al.

ONCOGENE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

Scott J. Dixon et al.

CELL (2012)

Add to Collection

Review Cell Biology

Regulating the regulator: post-translational modification of RAS

Ian M. Ahearn et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)

Add to Collection

Article Oncology

Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence

Carmen Guerra et al.

CANCER CELL (2011)

Add to Collection

Article Biochemistry & Molecular Biology

The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells

Michelangelo Cordenonsi et al.

CELL (2011)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, Research & Experimental

Dose and context dependent effects of Myc on epidermal stem cell proliferation and differentiation

Melanie A. Berta et al.

EMBO MOLECULAR MEDICINE (2010)

Add to Collection

Article Oncology

Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras

Sharon Y. Gidekel Friedlander et al.

CANCER CELL (2009)

Add to Collection

Article Gastroenterology & Hepatology

Basic-liver, pancreas, and biliary tract

Oliver Strobel et al.

GASTROENTEROLOGY (2007)

Add to Collection

Article Oncology

Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinorna by k-Ras Oncogenes in adult mice

Carmen Guerra et al.

CANCER CELL (2007)

Add to Collection

Article Chemistry, Multidisciplinary

Comparison of novel delivery systems for antisense peptide nucleic acids

L Chiarantini et al.

JOURNAL OF CONTROLLED RELEASE (2005)

Add to Collection

Review Biotechnology & Applied Microbiology

The cyclophilins

P Wang et al.

GENOME BIOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.